D. Marzo, V. Goparaju, S. Wang, L. Liu, J. Batkai et al., Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature, vol.410, issue.6830, pp.822-825, 2001.
DOI : 10.1038/35071088

N. Jamshidi and D. Taylor, Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats, British Journal of Pharmacology, vol.143, issue.6, pp.1151-1154, 2001.
DOI : 10.1038/sj.bjp.0704379

C. Williams and T. Kirkham, Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors, Psychopharmacology, vol.143, issue.3, pp.315-317, 1999.
DOI : 10.1007/s002130050953

C. Curioni and C. Andre, Rimonabant for overweight or obesity, Cochrane Database Syst Rev, vol.273, issue.4, p.6162, 2006.
DOI : 10.1002/14651858.CD006162.pub2

R. Padwal and S. Majumdar, Drug treatments for obesity: orlistat, sibutramine, and rimonabant, The Lancet, vol.369, issue.9555, pp.71-77, 2007.
DOI : 10.1016/S0140-6736(07)60033-6

M. Gary-bobo, G. Elachouri, J. Gallas, P. Janiak, P. Marini et al., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007.
DOI : 10.1002/hep.21641

B. Poirier, J. Bidouard, C. Cadrouvele, X. Marniquet, B. Staels et al., The anti-obesity effect of rimonabant is associated with an improved serum lipid profile, Diabetes, Obesity and Metabolism, vol.103, issue.1, pp.65-72, 2005.
DOI : 10.1074/jbc.M209033200

R. Trillou, C. Arnone, M. Delgorge, C. Gonalons, N. Keane et al., Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, vol.284, issue.2, pp.345-353, 2003.
DOI : 10.1152/ajpregu.00545.2002

J. Despres, A. Golay, and L. Sjostrom, Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia, New England Journal of Medicine, vol.353, issue.20, pp.2121-2134, 2005.
DOI : 10.1056/NEJMoa044537

V. Gaal, L. Rissanen, A. Scheen, A. Ziegler, O. Rossner et al., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, The Lancet, vol.365, issue.9468, pp.1389-1397, 2005.
DOI : 10.1016/S0140-6736(05)66374-X

R. Christensen, P. Kristensen, E. Bartels, H. Bliddal, and A. Astrup, Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials, The Lancet, vol.370, issue.9600, pp.1706-1713, 2007.
DOI : 10.1016/S0140-6736(07)61721-8

D. Marzo, V. Despres, and J. , CB1 antagonists for obesity???what lessons have we learned from rimonabant?, Nature Reviews Endocrinology, vol.14, issue.11, pp.633-638, 2009.
DOI : 10.1038/nrendo.2009.197

T. Jourdan, L. Djaouti, L. Demizieux, J. Gresti, B. Verges et al., CB1 Antagonism Exerts Specific Molecular Effects on Visceral and Subcutaneous Fat and Reverses Liver Steatosis in Diet-Induced Obese Mice, Diabetes, vol.59, issue.4, pp.926-934, 2010.
DOI : 10.2337/db09-1482
URL : https://hal.archives-ouvertes.fr/inserm-01344504

I. Matias, T. Bisogno, D. Marzo, and V. , Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake, International Journal of Obesity, vol.258, issue.1, pp.7-12, 2006.
DOI : 10.1038/nn1457

R. Nogueiras, C. Veyrat-durebex, P. Suchanek, M. Klein, J. Tschop et al., Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats, Diabetes, vol.57, issue.11, pp.2977-2991, 2008.
DOI : 10.2337/db08-0161

D. Osei-hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-white et al., Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice, Journal of Clinical Investigation, vol.118, issue.9, pp.3160-3169, 2008.
DOI : 10.1172/JCI34827

J. Tam, V. Vemuri, J. Liu, S. Batkai, B. Mukhopadhyay et al., Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity, Journal of Clinical Investigation, vol.120, issue.8, pp.2953-2966, 2010.
DOI : 10.1172/JCI42551DS1

L. Djaouti, J. T. Demizieux, L. Chevrot, M. Gresti, J. Verges et al., Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants, Diabetes/Metabolism Research and Reviews, vol.277, issue.Pt 3, pp.297-305, 2010.
DOI : 10.1002/dmrr.1081

J. Folch, M. Lees, S. Stanley, and G. , A simple method for the isolation and purification of total lipides from animal tissues, J Biol Chem, vol.226, pp.497-509, 1957.

I. Niot, J. Gresti, J. Boichot, G. Sempore, G. Durand et al., Effect of dietary n???3 and n???6 polyunsaturated fatty acids on lipid-metabolizing enzymes in obese rat liver, Lipids, vol.38, issue.7, pp.481-489, 1994.
DOI : 10.1007/BF02578245

T. Jourdan, L. Djaouti, L. Demizieux, J. Gresti, B. Verges et al., Liver Carbohydrate and Lipid Metabolism of Insulin-Deficient Mice Is Altered by trans-10, cis-12 Conjugated Linoleic Acid, Journal of Nutrition, vol.139, issue.10, pp.1901-1907, 2009.
DOI : 10.3945/jn.109.111062

L. Demizieux, P. Degrace, J. Gresti, O. Loreau, J. Noel et al., Conjugated linoleic acid isomers in mitochondria: evidence for an alteration of fatty acid oxidation, The Journal of Lipid Research, vol.43, issue.12, pp.2112-2122, 2002.
DOI : 10.1194/jlr.M200170-JLR200

P. Degrace, B. Moindrot, I. Mohamed, J. Gresti, Z. Du et al., Upregulation of liver VLDL receptor and FAT/CD36 expression in LDLR-/- apoB100/100 mice fed trans-10,cis-12 conjugated linoleic acid, The Journal of Lipid Research, vol.47, issue.12, pp.2647-2655, 2006.
DOI : 10.1194/jlr.M600140-JLR200

M. Bifulco, C. Laezza, G. Portella, M. Vitale, P. Orlando et al., Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth, The FASEB Journal, vol.15, pp.2745-2747, 2001.
DOI : 10.1096/fj.01-0320fje

B. Mukhopadhyay, J. Liu, D. Osei-hyiaman, G. Godlewski, P. Mukhopadhyay et al., Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-??, Journal of Biological Chemistry, vol.285, issue.25, pp.19002-19011, 2010.
DOI : 10.1074/jbc.M109.068460

C. Wu, D. Okar, J. Kang, and A. Lange, Reduction of Hepatic Glucose Production as a Therapeutic Target in the Treatment of Diabetes, Current Drug Targets - Immune, Endocrine & Metabolic Disorders, vol.5, issue.1, pp.51-59, 2005.
DOI : 10.2174/1568008053174769

D. Osei-hyiaman, M. Depetrillo, P. Pacher, J. Liu, S. Radaeva et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, Journal of Clinical Investigation, vol.115, issue.5, pp.1298-1305, 2005.
DOI : 10.1172/JCI200523057

P. Iynedjian, D. Jotterand, T. Nouspikel, M. Asfari, and P. Pilot, Transcriptional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system, J Biol Chem, vol.264, pp.21824-21829, 1989.

M. Magnuson, T. Andreone, R. Printz, S. Koch, and D. Granner, Rat glucokinase gene: structure and regulation by insulin., Proceedings of the National Academy of Sciences, vol.86, issue.13, pp.4838-4842, 1989.
DOI : 10.1073/pnas.86.13.4838

J. Seoane, A. Gomez-foix, O. Doherty, R. Gomez-ara, C. Newgard et al., Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase, J Biol Chem, vol.271, pp.23756-23760, 1996.

M. Foretz, C. Guichard, P. Ferre, and F. Foufelle, Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes, Proceedings of the National Academy of Sciences, vol.96, issue.22, pp.12737-12742, 1999.
DOI : 10.1073/pnas.96.22.12737

J. Girard, P. Ferre, and F. Foufelle, MECHANISMS BY WHICH CARBOHYDRATES REGULATE EXPRESSION OF GENES FOR GLYCOLYTIC AND LIPOGENIC ENZYMES, Annual Review of Nutrition, vol.17, issue.1, pp.325-352, 1997.
DOI : 10.1146/annurev.nutr.17.1.325

W. Krone and H. Greten, Evidence for post-transcriptional regulation by insulin of 3-hydroxy-3-methylglutaryl coenzyme A reductase and sterol synthesis in human mononuclear leucocytes, Diabetologia, vol.26, issue.5, pp.366-369, 1984.
DOI : 10.1007/BF00266038

A. Maitra, H. Lavoie, R. Day, J. Garmey, and J. Veldhuis, Regulation of porcine granulosa cell 3-hydroxy-3-methylglutaryl coenzyme A reductase by insulin and insulin-like growth factor I: synergism with follicle-stimulating hormone or protein kinase A agonist, Endocrinology, vol.136, pp.5111-5117, 1995.

S. Shetty, E. Eckhardt, S. Post, and D. Van-der-westhuyzen, Phosphatidylinositol-3-Kinase Regulates Scavenger Receptor Class B Type I Subcellular Localization and Selective Lipid Uptake in Hepatocytes, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.9, pp.2125-2131, 2006.
DOI : 10.1161/01.ATV.0000233335.26362.37

G. Lambert, M. Chase, K. Dugi, A. Bensadoun, H. Brewer et al., Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1, J Lipid Res, vol.40, pp.1294-1303, 1999.

A. Vidal-puig, R. Considine, M. Jimenez-linan, A. Werman, W. Pories et al., Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids., Journal of Clinical Investigation, vol.99, issue.10, pp.2416-2422, 1997.
DOI : 10.1172/JCI119424

B. Perret, L. Mabile, L. Martinez, F. Terce, R. Barbaras et al., Hepatic lipase: structure/function relationship, synthesis, and regulation, J Lipid Res, vol.43, pp.1163-1169, 2002.

K. Sugamura, S. Sugiyama, Y. Fujiwara, J. Matsubara, E. Akiyama et al., Cannabinoid 1 Receptor Blockade Reduces Atherosclerosis with Enhances Reverse Cholesterol Transport, Journal of Atherosclerosis and Thrombosis, vol.17, issue.2, pp.141-147, 2010.
DOI : 10.5551/jat.2865

K. Kashfi, R. Mynatt, and G. Cook, Hepatic carnitine palmitoyltransferase-I has two independent inhibitory binding sites for regulation of fatty acid oxidation, Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, vol.1212, issue.2, pp.245-252, 1994.
DOI : 10.1016/0005-2760(94)90259-3

M. Murthy and S. Pande, Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane., Proceedings of the National Academy of Sciences, vol.84, issue.2, pp.378-382, 1987.
DOI : 10.1073/pnas.84.2.378

R. Brownsey, A. Boone, J. Elliott, J. Kulpa, and W. Lee, Regulation of acetyl-CoA carboxylase: Table 1, Biochemical Society Transactions, vol.34, issue.2, pp.223-227, 2006.
DOI : 10.1042/BST0340223

T. Watanabe, N. Kubota, M. Ohsugi, T. Kubota, I. Takamoto et al., Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways, Journal of Biological Chemistry, vol.284, issue.3, pp.1803-1812, 2009.
DOI : 10.1074/jbc.M807120200

L. Groop, R. Bonadonna, S. Delprato, K. Ratheiser, K. Zyck et al., Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance., Journal of Clinical Investigation, vol.84, issue.1, pp.205-213, 1989.
DOI : 10.1172/JCI114142

B. Mukhopadhyay, R. Cinar, S. Yin, J. Liu, J. Tam et al., Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver, Proceedings of the National Academy of Sciences, vol.108, issue.15, pp.6323-6328, 2011.
DOI : 10.1073/pnas.1017689108

M. Bouaboula, S. Perrachon, L. Milligan, X. Canat, M. Rinaldi-carmona et al., A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1: EVIDENCE FOR A NEW MODEL OF RECEPTOR/LIGAND INTERACTIONS, Journal of Biological Chemistry, vol.272, issue.35, pp.22330-22339, 1997.
DOI : 10.1074/jbc.272.35.22330

L. Sim-selley, L. Brunk, and D. Selley, Inhibitory effects of SR141716A on G-protein activation in rat brain, European Journal of Pharmacology, vol.414, issue.2-3, pp.135-143, 2001.
DOI : 10.1016/S0014-2999(01)00784-1

I. Esposito, M. Proto, P. Gazzerro, C. Laezza, C. Miele et al., The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase, Molecular Pharmacology, vol.74, issue.6, pp.1678-1686, 2008.
DOI : 10.1124/mol.108.049205